Gene Therapy Brings New Hope for Active Kids

Quick Smiles:

• Children and teens with spinal muscular atrophy gained newfound movement after a single-dose gene therapy.
• The trial saw significant improvements in walking, standing, and climbing stairs in participants aged 2 to 18.
• Researchers recommend expanding therapy access to older kids for lasting impact.

A groundbreaking clinical trial has shown that a single-dose gene therapy can dramatically enhance movement abilities in children and teenagers with spinal muscular atrophy, even beyond the age of two.

Many participants who could previously only sit were able to stand, walk, and climb stairs after treatment, revealing possibilities they had never experienced before.

This promising therapy, known as onasemnogene abeparvovec, was delivered directly into the spinal fluid, offering a potential alternative to lifelong, repeat treatments and their associated financial strains.

Dr. Richard Finkel and colleagues at St. Jude Children’s Research Hospital led the year-long study with 126 children and adolescents between 2 and 18 years old, comparing the gene therapy to a placebo.

Those who received the gene therapy showed notable improvement in 33 specific motor skills compared to those who did not, demonstrating how effective this treatment can be for older children.

“We recommend broadening access to this gene therapy for spinal muscular atrophy to patients beyond infancy, addressing an unmet need in older children and adolescents,” Dr. Finkel states.

Side effects were generally manageable in all groups, though future long-term studies are needed for further evaluation.

This vital advancement offers renewed optimism and support for children and families affected by this rare disorder.

If you’re inspired by these breakthroughs, share the good news and encourage hope for even more families in the future!

Source